ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib and ponatinib (19–21, Table 1), as new-generation TKIs, have unique activity against the T315I mutation and are approved to treat patients with resistance or intolerance to prior TKI therapy or the presence of the BCR-ABL1 T315I mutation in all CML phases.